: Merial News Release
News Release
New Vaccine Provides Superior Booster to Killed Vaccine

May 10, 2004

Duluth, Ga. — Recently completed research shows that RECOMBITEK® Equine West Nile Virus vaccine effectively boosters horses against West Nile Virus (WNV), regardless of the previously used vaccine. A head-to-head comparison study demonstrated higher titers for equine WNV with the use of RECOMBITEK Equine WNV, a recombinant-vectored virus vaccine, versus a killed virus product.1

"We are confident that one dose of RECOMBITEK Equine WNV vaccine quickly and effectively stimulates the horse's immune system against WNV, even if the horse was previously vaccinated with a killed virus product," says Stephanie Thompson, DVM, Veterinary Technical Solutions Manager for Merial.

In the comparison study, horses that previously received a two-dose series of the killed vaccine were given a booster shot of either RECOMBITEK Equine WNV or the killed vaccine. Horses receiving the RECOMBITEK Equine WNV vaccination exhibited significantly higher levels of antibodies on Day 14 post vaccination. The killed vaccine showed a 4.38-fold increase in titers on Day 14, while RECOMBITEK demonstrated a 6.21-fold increase. (See accompanying chart.)

Electronic copies of above chart are available upon request.

1Data on file at Merial.

®RECOMBITEK is a registered trademark of Merial.

For further information please contact:

Cindy Apgar
(678) 638-3690

Josh Krenz
(262) 784-7200

Merial is a world-leading innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 6,000 people and operates in more than 150 countries worldwide. Its 2003 sales were in excess of $1.8 billion. Merial Limited is a joint venture between Merck & Co., Inc. and Aventis, S.A. For more information, please see

Back to Top
Print          Close Window